RZLT Stock Analysis: Rezolute | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 473m USD | 12M Return: -0.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rezolute, Inc. (NASDAQ: RZLT) is a late-stage rare disease biopharmaceutical company developing therapies for hypoglycemia driven by hyperinsulinism. The companys lead candidate, ersodetug, is an intravenously administered human monoclonal antibody currently in Phase 3 development for congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, with additional clinical work targeting tumor-related hyperinsulinism. The rare disease business model typically targets small patient populations under orphan drug frameworks, often relying on regulatory designations such as Orphan Drug and Breakthrough Therapy to support development and potential pricing power.
Founded in 2010 and headquartered in Redwood City, California, Rezolute was previously known as AntriaBio, Inc. before rebranding in December 2017. As a clinical-stage biotechnology company, its value is largely tied to the progression and regulatory outcome of ersodetug, with limited near-term revenue given the absence of approved products.
- Phase 3 ersodetug data readout for congenital hyperinsulinism approaches
- FDA regulatory milestones for ersodetug BLA submission progress
- Cash burn forces dilutive financing amid late-stage trial costs
| Net Income: -81.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.59 > 0.02 and ΔFCF/TA 10.67 > 1.0 |
| NWC/Revenue: 249k% < 20% (prev 135k%; Δ 114k% < -1%) |
| CFO/TA -0.59 > 3% & CFO -73.5m > Net Income -81.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.0m) vs 12m ago 48.56% < -2% |
| Gross Margin: 32.61% > 18% (prev 48.28%; Δ -15.67% > 0.5%) |
| Asset Turnover: 0.04% > 50% (prev 0.06%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 122.0m - Total Current Liabilities 7.70m) / Total Assets 125.5m |
| B: -3.67 (Retained Earnings -461.0m / Total Assets 125.5m) |
| C: -0.74 (EBIT TTM -81.5m / Avg Total Assets 110.1m) |
| D: 13.55 (Book Value of Equity 116.8m / Total Liabilities 8.62m) |
| Altman-Z'' = 3.25 = A |
| DSRI: 1.08 (Receivables 600k/700k, Revenue 46.0k/58.0k) |
| GMI: 1.48 (GM 48.28% / 32.61%) |
| AQI: 0.42 (AQ_t 0.02 / AQ_t-1 0.05) |
| SGI: 0.79 (Revenue 46.0k / 58.0k) |
| TATA: -0.06 (NI -81.5m - CFO -73.5m) / TA 125.5m) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 4.97 with a total of 1,536,813 shares traded. Over the past week, the price has changed by -2.55%, over one month by +21.81%, over three months by +50.61% and over the past year by -0.20%.
Current recommended Stop Loss: 4.50 (which is 9.5% or 1.4 ATR below the current price).
Rezolute has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy RZLT.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.7 | 54.3% |
P/B = 4.055
Revenue TTM = 46.0k USD
EBIT TTM = -81.5m USD
EBITDA TTM = -81.5m USD
Long Term Debt = 438k USD (estimated: total debt 1.11m - short term 673k)
Short Term Debt = 673k USD (from shortTermDebt, last quarter)
Debt = 1.11m USD (from shortLongTermDebtTotal, last quarter) (leases 1.11m already included)
Net Debt = -119.2m USD (calculated: Debt 1.11m - CCE 120.3m)
Enterprise Value = 353.6m USD (472.8m + Debt 1.11m - CCE 120.3m)
Interest Coverage Ratio = unknown (Ebit TTM -81.5m / Interest Expense TTM 0.0)
EV/FCF = -4.81x (Enterprise Value 353.6m / FCF TTM -73.5m)
FCF Yield = -20.78% (FCF TTM -73.5m / Enterprise Value 353.6m)
FCF Margin = -160k% (FCF TTM -73.5m / Revenue TTM 46.0k)
Net Margin = -177k% (Net Income TTM -81.5m / Revenue TTM 46.0k)
Gross Margin = 32.61% ((Revenue TTM 46.0k - Cost of Revenue TTM 31.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.82 (Enterprise Value 353.6m / Total Assets 125.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.11m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -64.4m (EBIT -81.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.84 (Total Current Assets 122.0m / Total Current Liabilities 7.70m)
Debt / Equity = 0.01 (Debt 1.11m / totalStockholderEquity, last quarter 116.8m)
Debt / EBITDA = 1.46 (negative EBITDA) (Net Debt -119.2m / EBITDA -81.5m)
Debt / FCF = 1.62 (negative FCF - burning cash) (Net Debt -119.2m / FCF TTM -73.5m)
Total Stockholder Equity = 138.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -74.01% (Net Income -81.5m / Total Assets 125.5m)
RoE = -58.82% (Net Income TTM -81.5m / Total Stockholder Equity 138.5m)
RoCE = -58.64% (EBIT -81.5m / Capital Employed (Equity 138.5m + L.T.Debt 438k))
RoIC = -54.36% (negative operating profit) (NOPAT -64.4m / Invested Capital 118.4m)
WACC = 14.19% (E(472.8m)/V(473.9m) * Re(14.22%) + D(1.11m)/V(473.9m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.22% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 89.89 | Cagr: 36.80%
[DCF] Fair Price = unknown (Cash Flow -73.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.18 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.15 | Chg30d=+26.26% | Revisions=+50% | Analysts=5
EPS current Year (2026-06-30): EPS=-0.69 | Chg30d=-0.52% | Revisions=+30% | GrowthEPS=+29.1% | GrowthRev=+0.0%
EPS next Year (2027-06-30): EPS=-0.63 | Chg30d=+0.98% | Revisions=+30% | GrowthEPS=+9.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +45% (up=13, down=4)